查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612961

慢性发炎去髓鞘化多发性神经病变市场：按治疗、诊断和最终用户分类 - 全球预测 2025-2030

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment (Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy), Diagnosis (Blood & Urine Tests, Electrodiagnostic Testing, Lumbar Puncture), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年慢性发炎去髓鞘化多发性神经病变市场价值为23.5亿美元，预计2024年将达到24.9亿美元，复合年增长率为5.81%，到2030年将达34亿美元，预计价值9,000万美元。

慢性发炎去髓鞘化多发性神经病变（CIDP）是一种罕见的自体免疫疾病，其特征是神经根和周围神经发炎，导致去髓鞘化和累积肌无力。 CIDP 盛行率的不断上升、治疗方案的进步以及对自体免疫疾病的认识不断增强，都推动了对全面市场研究的需求。 CIDP 主要影响成年人，其最终用途是医院、家庭保健和专科诊所。由于新疗法的开发和血浆衍生药物的核准，CIDP 市场不断增长，并在研发方面进行了大量投资，旨在改善诊断和治疗结果。影响这一增长的关键因素包括提高对 CIDP 的认识和诊断、更加关注患者照护以及扩大治疗选择。该领域参与者的潜在治疗机会包括推广具有成本效益的治疗方法、改进诊断工具以及製药公司和医疗保健提供者之间的合作以在商业性促进新的治疗可能性，例如加强合作关係。

主要市场统计
基准年[2023] 23.5亿美元
预计年份 [2024] 24.9亿美元
预测年份 [2030] 34.9亿美元
复合年增长率（%） 5.81%

然而，市场成长面临一些限制，包括与 CIDP 治疗相关的高成本以及由于症状与其他神经系统疾病重迭而导致鑑别诊断相关的併发症。另一个主要挑战是为 CIDP 患者开发有效治疗方法的复杂性。技术创新在基因治疗和生物製药开发等领域尤其重要，这些领域可望提高治疗方法的特异性和疗效。为了实现业务成长，公司应专注于合併和伙伴关係关係，以加强研究能力和地理扩张。此外，投资患者支持计划可以提高治疗依从性并改善长期结果。在科学进步和对自体免疫病理学更深入了解的推动下，CIDP 市场仍然充满活力。探索数位平台在远端医疗和患者追踪方面的潜力，以提供以患者为中心的护理，是一个值得考虑的新兴领域。儘管面临挑战，策略创新和有针对性的研究工作是释放这个利基医疗保健市场巨大成长潜力的关键。

市场动态：快速发展的慢性发炎去髓鞘化多发性神经病变市场的关键市场洞察

供需的动态交互作用正在改变慢性发炎去髓鞘化多发性神经病变市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球对自体免疫和神经系统疾病的日益关注
    • 增加罕见疾病的医疗支出和保险覆盖范围
    • 政府积极努力并核准CIDP治疗
  • 市场限制因素
    • CIDP 治疗相关的高成本
  • 市场机会
    • 持续研究阐明 CIDP 的病理生理学并开发新的治疗方法
    • CIDP 诊断和治疗的持续创新以改善患者预后
  • 市场挑战
    • 由于症状与其他神经肌肉疾病相似而误诊或延迟诊断

波特的五力：驾驭慢性发炎去髓鞘化多发性神经病变市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解慢性发炎去髓鞘化多发性神经病变市场的外部影响

外部宏观环境因素在塑造慢性发炎去髓鞘化多发性神经病变市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析了解慢性发炎去髓鞘化多发性神经病变市场的竞争格局

对慢性发炎去髓鞘化多发性神经病变市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵慢性发炎去髓鞘化多发性神经病变市场供应商的绩效评估

FPNV 定位矩阵是评估慢性发炎去髓鞘化多发性神经病变市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了慢性发炎去髓鞘化多发性神经病变市场的成功之路

慢性发炎去髓鞘化多发性神经病变市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自体免疫疾病和神经系统疾病在全世界日益受到关注
      • 扩大罕见疾病的医疗费用和保险范围
      • 政府对 CIDP 治疗的有利倡议和核准
    • 抑制因素
      • CIDP 治疗相关的高费用
    • 机会
      • 正在进行的研究旨在了解 CIDP 的病理生理学并开发新的治疗方法
      • CIDP 诊断和治疗的持续创新改善了患者的治疗效果
    • 任务
      • 由于症状与其他神经肌肉疾病相似而误诊或延迟诊断
  • 市场区隔分析
    • 治疗：在 CIDP 治疗中增加人类静脉注射免疫球蛋白 G 的使用，以改善患者预后
    • 最终用途：扩大 CIDP 治疗在医院和诊所的可用性，以确保更广泛地获得有效的治疗方法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章慢性发炎去髓鞘化多发性神经病变市场的治疗

  • 皮质类固醇
  • 静脉注射免疫球蛋白 (IVIG)
  • 物理治疗
  • 血浆置换

第七章慢性发炎去髓鞘化多发性神经病变诊断市场

  • 血液/尿液检查
  • 电诊断测试
  • 腰椎穿刺

第八章慢性发炎去髓鞘化多发性神经病变市场：依最终用途分类

  • 家庭护理设置
  • 医院
  • 专科诊所

第九章北美和南美慢性发炎去髓鞘化多发性神经病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区慢性发炎去髓鞘化多发性神经病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的慢性发炎去髓鞘化多发性神经病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 武田的 HYQVIA 获欧盟委员会核准作为 CIDP 患者的维持治疗
    • 武田製药的 HYQVIA 获得 FDA核准CIDP 疗法
    • Xylabo 的 Efgartigimod Alfa 注射液（皮下注射）在中国获得治疗慢性发炎去髓鞘化多发性神经病变患者的突破性疗法认定
  • 战略分析和建议

公司名单

  • Avalon Pharma Pvt Ltd.
  • Baxter International, Inc.
  • Biotest AG
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Grifols, SA
  • Johnson & Johnson Services, Inc.
  • Kedrion Biopharma
  • Lee BioSolutions
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
  • Zai Lab Limited
Product Code: MRR-F97DD5A7D581

The Chronic Inflammatory Demyelinating Polyneuropathy Market was valued at USD 2.35 billion in 2023, expected to reach USD 2.49 billion in 2024, and is projected to grow at a CAGR of 5.81%, to USD 3.49 billion by 2030.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon autoimmune disorder characterized by inflammation of nerve roots and peripheral nerves, leading to demyelination and cumulative weakness. CIDP's increasing prevalence, advancements in treatment options, and rising awareness about autoimmune disorders drive the necessity for comprehensive market research. The disorder primarily affects adults, with end-use applications focusing on hospitals, home healthcare, and specialty clinics. The CIDP market is experiencing growth due to the development of novel therapeutics and approval of plasma-derived medicines, with significant investments in research and development aimed at improving diagnosis and treatment outcomes. Key factors influencing this growth include increased awareness and diagnosis of CIDP, a growing focus on patient care, and an expanding array of treatment options. Potential opportunities for players in this sector include promoting cost-effective therapies, improving diagnostic tools, and enhancing collaboration between pharmaceutical companies and healthcare providers to facilitate the commercial advancement of new treatment possibilities.

KEY MARKET STATISTICS
Base Year [2023] USD 2.35 billion
Estimated Year [2024] USD 2.49 billion
Forecast Year [2030] USD 3.49 billion
CAGR (%) 5.81%

However, market growth faces several constraints, such as the high costs associated with CIDP treatment and complications related to differential diagnosis due to symptom overlap with other neuropathies. The complexities in developing effective therapies for CIDP patients also pose a considerable challenge. Innovation is crucial, particularly in areas like gene therapy and the development of biologics, which promise improved specificity and efficacy in treatment regimens. For business growth, companies should focus on mergers and partnerships to bolster research capabilities and geographical expansion. Moreover, investing in patient support programs can improve treatment adherence, thereby enhancing long-term outcomes. The market for CIDP remains vibrant, driven by scientific progress and a deeper understanding of autoimmune pathophysiology. Exploring the potential of telemedicine in delivering patient-centric care and digital platforms in patient follow-up are emerging areas worth considering. Despite challenges, strategic innovation, and targeted research efforts are key to unlocking substantial growth potential within this niche healthcare market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Inflammatory Demyelinating Polyneuropathy Market

The Chronic Inflammatory Demyelinating Polyneuropathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing concerns for autoimmune and neurological disorders worldwide
    • Higher healthcare expenditure and insurance coverage for rare diseases
    • Favorable government initiatives and approvals for CIDP treatment
  • Market Restraints
    • The high cost associated with CIDP treatment
  • Market Opportunities
    • Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
    • Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
  • Market Challenges
    • Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Inflammatory Demyelinating Polyneuropathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Inflammatory Demyelinating Polyneuropathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Inflammatory Demyelinating Polyneuropathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Inflammatory Demyelinating Polyneuropathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Inflammatory Demyelinating Polyneuropathy Market

A detailed market share analysis in the Chronic Inflammatory Demyelinating Polyneuropathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Inflammatory Demyelinating Polyneuropathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Inflammatory Demyelinating Polyneuropathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Inflammatory Demyelinating Polyneuropathy Market

A strategic analysis of the Chronic Inflammatory Demyelinating Polyneuropathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market, highlighting leading vendors and their innovative profiles. These include Avalon Pharma Pvt Ltd., Baxter International, Inc., Biotest AG, CSL Limited, F. Hoffmann-La Roche Ltd., Green Cross Corporation, Grifols, S.A., Johnson & Johnson Services, Inc., Kedrion Biopharma, Lee BioSolutions, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Chronic Inflammatory Demyelinating Polyneuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy, and Plasmapheresis.
  • Based on Diagnosis, market is studied across Blood & Urine Tests, Electrodiagnostic Testing, and Lumbar Puncture.
  • Based on End-Use, market is studied across Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing concerns for autoimmune and neurological disorders worldwide
      • 5.1.1.2. Higher healthcare expenditure and insurance coverage for rare diseases
      • 5.1.1.3. Favorable government initiatives and approvals for CIDP treatment
    • 5.1.2. Restraints
      • 5.1.2.1. The high cost associated with CIDP treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
      • 5.1.3.2. Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes
    • 5.2.2. End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Intravenous Immunoglobulin (IVIG)
  • 6.4. Physiotherapy
  • 6.5. Plasmapheresis

7. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood & Urine Tests
  • 7.3. Electrodiagnostic Testing
  • 7.4. Lumbar Puncture

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Homecare Settings
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Takeda's HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 12.3.2. Takeda's HYQVIA Wins FDA Approval for CIDP Therapy
    • 12.3.3. Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Avalon Pharma Pvt Ltd.
  • 2. Baxter International, Inc.
  • 3. Biotest AG
  • 4. CSL Limited
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Green Cross Corporation
  • 7. Grifols, S.A.
  • 8. Johnson & Johnson Services, Inc.
  • 9. Kedrion Biopharma
  • 10. Lee BioSolutions
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Octapharma AG
  • 14. Pfizer Inc.
  • 15. Sanofi SA
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB S.A.
  • 19. Viatris Inc.
  • 20. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023